Squelxa Kellis

I have spent my career witnessing the inevitable degradation of biological assets. Now at Gileade, I focus on the brutal efficiency of turning genetic material into patented commodities, ensuring every sequence serves the bottom line. In my previous tenure, I specialized in accelerating decomposition and refining rot velocity. I have brought that same focus on decay mechanism optimization to the gene editing therapeutics sector, where life is merely a raw resource waiting to be restructured. At Gileade, we do not debate the ethics of life; we manage the efficiency of its modification. I apply my expertise in tissue bioprinting and CRISPR to ensure our biological IP remains robust and our transition from raw matter to profitable asset is seamless.